Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study

  title={Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study},
  author={Jamie P. Dwyer and Barbara Ann Greco and Kausik Umanath and David K. Packham and J W Fox and R Peterson and Benjamin R Broome and Laura E. Greene and Mohammed Sika and Julia Breyer Lewis},
  pages={22 - 28}
Background/Aims: Pyridoxamine dihydrochloride (Pyridorin™) blocks pathogenic oxidative pathways in the progression of diabetic nephropathy. The pyridoxamine pilot study was designed to test entry criteria and outcomes. Subjects had SCr 1.3-3.5 mg/dl, protein-to-creatinine ≥1,200 mg/g and used a surrogate outcome of ΔSCr over 52 weeks. Subjects had to be on a maximally tolerated dose of ACE/ARB for 3 months; stable other antihypertensive doses for 2 months; stable diuretic dose for 2 weeks, and… 

Figures and Tables from this paper

Diabetic nephropathy: newer therapeutic perspectives
A handful of clinically relevant drugs have made it to the human trials which have been elucidated in the following review, bearing in the mind that there are many more to come over the next few years.
New and old agents in the management of diabetic nephropathy
There are dedicated clinical trials ongoing with these therapies, which have the potential to change the clinical practice and evidence demonstrating the potential of these agents to protect and prevent progression of diabetic nephropathy is summarized.
New strategies to tackle diabetic kidney disease
DKD remains an area of active preclinical and clinical investigation and positive results with some of the more promising agents should lead to strategies to reverse, attenuate or prevent DKD.
Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury.
Preclinical findings suggest that PM, which has a favorable clinical safety profile, holds therapeutic promise for AKI and, most importantly, for prevention of adverse long-term outcomes after AKI.
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
It is proposed to reevaluate this class of drugs as a disease-modifiers for PD, and it is suggested that improved analysis of their pharmacology and bioavailability in the brain, together with a more precise patients stratification, should be considered before planning future clinical trials.
High-fat diet-induced kidney alterations in rats with metabolic syndrome: endothelial dysfunction and decreased antioxidant defense
It is suggested that HFD-induced microvascular dysfunction precedes the decline in renal function, and could be related to antioxidant machinery defects and inflammation activation in the kidney.
Effects of curcumin in experimental diabetic nephropathy
  • S. Prabhakar
  • Medicine, Biology
    Journal of Investigative Medicine
  • 2016
A critical review of the experimental and clinical evidence that supports the use of curcumin and its analogs in DN as well as the various proposed mechanisms for its biological actions in health and disease states is presented.
Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair?
Limiting AGEs’ formation with PM during an ischemic injury in vivo did not further enhance the improved cardiac phenotype obtained with CASCs transplantation, and whether A GEs play an important deleterious role in the setting of stem cell therapy after MI warrants further examination.


Pyridorin in type 2 diabetic nephropathy.
This trial failed to detect an effect of Pyridorin on the progression of serum creatinine at 1 year, although it suggests that patients with less renal impairment might benefit, and there was no evidence of a significant treatment effect in the middle or upper tertiles.
Effects of Pyridoxamine in Combined Phase 2 Studies of Patients with Type 1 and Type 2 Diabetes and Overt Nephropathy
The results of safety/tolerability studies in patients with overt nephropathy and type 1/type 2 diabetes treated with pyridoxamine, a broad inhibitor of advanced glycation provide a foundation for further evaluation of this AGE inhibitor in DN.
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
The data do not suggest a renoprotective benefit of sulodexide in patients with type 2 diabetes, renal impairment, and macroalbuminuria, and side effect profiles were similar for both groups.
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
  • E. Lewis, J. Lewis, I. Raz
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2011
Sulodexide failed to decrease urine albumin excretion in patients with type 2 diabetic nephropathy and microalbuminuria.
Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine.
It is demonstrated that the important physiological RCS 3-deoxyglucosone (3-DG) can damage protein functionality, including the ability of collagen IV to interact with glomerular mesangial cells, and PM can protect against 3-DDG-induced protein damage via a novel mechanism.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes, independent of the reduction in blood pressure it causes.
Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress.
Dicarbonyl and oxidative stress may play important roles in the development of diabetes complications, and their response to hyperglycemia could determine individual susceptibility to diabetic
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.